Our differentiated therapies have the potential to set new standards for efficacy and patient response rates across various difficult-to-treat cancers. The Company, established in 2017 is based on seminal research conducted at the Hebrew University of Jerusalem and the University of Rijeka. Our technology addresses major escape mechanisms of current IO therapies through a diverse pipeline of novel monoclonal antibodies (mAbs) and antibody-drug-conjugates (ADCs). In late 2022 we launched phase 1 of a clinical trial for NTX1088, our first-in-class anti-PVR targeted immunotherapy for the treatment of patients with advanced solid tumors together with MD Anderson and entered into a clinical trial collaboration agreement with MSD (Merck).
Nectin Therapeutics has an established scientific and management team with deep experience in oncology R&D, a successful track record in building biotech companies and developing innovative therapies. Nectin Therapeutics is a venture-backed, privately held company, funded by aMoon Fund, Peregrine Ventures, IBF, Integra Holdings, Cancer Focus Fund, and Myeloma Investment Fund.
A first-in-class mAb, directed against a key immune checkpoint, PVR (CD155). NTX1088 demonstrated superior antitumor activity compared to approved and investigational Immune Checkpoint Inhibitors (ICIs) in pre-clinical models. NTX1088 has a favorable safety profile in non-human primates (NHP). An ongoing phase 1 clinical trial is evaluating NXT1088 as a mono-therapy and in combination with KEYTRUDA® (pembrolizumab).
A best-in-class mAb, targeting CD112R (PVRIG), a novel immune inhibitory receptor. NTX2R13 demonstrated superior therapeutic potential with an initial clean safety profile in NHP. Along with their single agent activity, NTX1088 and NTX2R13 synergize with each other, and exhibit noticeable synergy with approved PD(L)1 blockers in various preclinical studies, raising the possibility for the development of combination immunotherapy.
Nectin Therapeutics is engaged in the development of a pipeline of first-in-class and best-in-class ADC therapies. Our candidates have demonstrated robust tumor regression in multiple in vivo models of solid and hematological malignancies. Our ADC programs are currently undergoing IND-enabling studies.